DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for primary ciliary dyskinesia 5 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrimary ciliary dyskinesia 5 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for primary ciliary dyskinesia 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Primary ciliary dyskinesia is a rare genetic disease that impairs cilia motility and mucociliary clearance. The vast majority of patients have not been diagnosed, and late diagnosis is common, by which time damage to the respiratory system has already occurred. There is no single gold standard diagnostic test, and symptoms are not disease-specific. The recommended test combination — nasal nitric oxide, genetic testing, and biopsy for electron or video microscopy — has historically been applied to only a few patients. A large international participatory study has assessed the current diagnostic situation, but the abstract does not report its numerical results.
Management of primary ciliary dyskinesia is not based on high-level evidence. Research findings come mostly from small observational studies with limited follow-up. An international registry has been established to systematically collect data on incidence, clinical presentation, treatment, and disease course, addressing a stated unmet need for such a platform. The registry abstract provides no outcome data.
No drug is mentioned in any of these abstracts. No treatment has been tested in a controlled trial for this condition. What is still missing is a reliable, widely accessible diagnostic pathway, high-quality evidence from randomised trials or large prospective cohorts, and sufficient funding to move beyond small observational studies and registry building.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Respiratory Review · 2017 · 72 citations · open access
Clinical care for primary ciliary dyskinesia: current challenges and future directions
AbstractPrimary ciliary dyskinesia (PCD) is a rare genetic disease that affects the motility of cilia, leading to impaired mucociliary clearance. It is estimated that the vast majority of patients with PCD have not been diagnosed as such, providing a major obstacle to delivering appropriate care. Challenges in diagnosing PCD include lack of disease-specific symptoms and absence of a single, "gold standard", diagnostic test. Management of patients is currently not based on high-level evidence because research findings are mostly derived from small observational studies with limited follow-up period. In this review, we provide a critical overview of the available literature on clinical care for PCD patients, including recent advances. We identify barriers to PCD research and make suggestions for overcoming challenges.
Tidsskrift for Den norske legeforening · 2016 · 1 citations · open access
Primær ciliedyskinesi
AbstractPrimary ciliary dyskinesia (PCD) is a rare disease, but causes symptoms that resemble far more common respiratory diseases. Late diagnosis is common, when damage to the respiratory system has already occurred. This article aims to elucidate the condition and the diagnostic methods available. The article is based on literature searches in PubMed and the author's own experience of patient treatment and clinical research.
Diagnostic testing in people with primary ciliary dyskinesia around the world: where do we stand?
AbstractIntroduction In the past, only few patients with primary ciliary dyskinesia (PCD) were diagnosed with the test combination recommended by guidelines (nasal nitric oxide (nNO), genetic testing, and biopsy for electron or video microscopy) [Halbeisen, ERJ, 2019]. In a large international participatory study of people with PCD, we assessed the current situation.
An international registry for primary ciliary dyskinesia
AbstractPrimary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder leading to chronic upper and lower airway disease. Fundamental data on epidemiology, clinical presentation, course and treatment strategies are lacking in PCD. We have established an international PCD registry to realise an unmet need for an international platform to systematically collect data on incidence, clinical presentation, treatment and disease course.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
